#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1
• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1

Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

• https://x.com/AurelieRheumo/status/1983553385505726631/photo/1

Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

• https://x.com/JihaRheum/status/1983553108535136270/photo/1

Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

• https://x.com/AurelieRheumo/status/1983552472221163564/photo/1

ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

• https://x.com/JihaRheum/status/1983551740202095038/photo/1

#YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd

• https://x.com/DrMiniDey/status/1983551437800923182/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/GXxmtoluBc

The DIPSA study: can diet improve PsA? Finally a RCT, and the general message is Loose weight, regardless of the diet! 3 arms: -Mediterranean diet 31pts -Low-calorie Dietary Approaches (DASH-LC) 30pts -Standard of care 31pts Primary outcome change in DAPSA wk 12 DASH-LC https://t.co/XH9Xdn0g96

• https://x.com/AurelieRheumo/status/1983550053856821317/photo/1

In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

• https://x.com/synovialjoints/status/1983549391203119443/photo/1

Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

• https://x.com/RichardPAConway/status/1983549389504135603/photo/1